<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The efficacy and tolerability of the <z:chebi fb="0" ids="50075">dihydropyridine</z:chebi> calcium <z:chebi fb="68" ids="48706">antagonist</z:chebi> nimodipine (BAY e 9736) in the prophylaxis of ischemic neurological deficits after <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> were investigated in 171 patients in an open, prospective, multicenter study </plain></SENT>
<SENT sid="1" pm="."><plain>68 of the patients had to be excluded from the efficacy assessment as they had failed to satisfy important inclusion criteria </plain></SENT>
<SENT sid="2" pm="."><plain>The efficacy assessment was based on 104 patients of Hunt and Hess grades I-III </plain></SENT>
<SENT sid="3" pm="."><plain>In 86 patients the ruptured <z:hpo ids='HP_0002617'>aneurysm</z:hpo> was clipped before or during the nimodipine therapy, while 18 patients did not undergo surgery owing to failure to detect an <z:hpo ids='HP_0002617'>aneurysm</z:hpo>, continuous deterioration of the clinical condition, or for other reasons </plain></SENT>
<SENT sid="4" pm="."><plain>At the end of the nimodipine treatment 74 of the patients (71%) were completely free from symptoms or had only very slight neurological deficits </plain></SENT>
<SENT sid="5" pm="."><plain>There were 10 patients (10%) with moderate and 10 with a severe disablement, 4 patients were apallic, and 6 (6%) died during the nimodipine treatment </plain></SENT>
<SENT sid="6" pm="."><plain>In 4 patients (3.8%) <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> was the sole cause of severe neurological deficits or <z:hpo ids='HP_0011420'>death</z:hpo>, while in a further 3 patients (2.7%) vasospasm and other serious complications were responsible for poor outcome </plain></SENT>
<SENT sid="7" pm="."><plain>22 of the 171 patients (12.9%) died during or shortly after nimodipine therapy </plain></SENT>
<SENT sid="8" pm="."><plain>Rebleeding occurred during nimodipine therapy in 7 of the 143 preoperatively treated cases (4.9%) </plain></SENT>
</text></document>